Experimental and calculated shift in pK(a) upon binding of phosphotyrosine peptide to the SH2 domain of p56(lck).
暂无分享,去创建一个
Malcolm B. Gillies | M. Fischer | Nico J de Mol | Malcolm B Gillies | Marcel J E Fischer | N. J. de Mol
[1] S. Shoelson,et al. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. , 1994, Biochemistry.
[2] P. Furet,et al. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1. , 2000, Bioorganic & medicinal chemistry letters.
[3] S. Harrison,et al. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck , 1993, Nature.
[4] M. Fischer,et al. Kinetic analysis of the mass transport limited interaction between the tyrosine kinase lck SH2 domain and a phosphorylated peptide studied by a new cuvette-based surface plasmon resonance instrument. , 2000, Analytical biochemistry.
[5] W. L. Jorgensen,et al. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.
[6] J. Forman-Kay,et al. pH Titration studies of an SH2 domain‐phosphopeptide complex: Unusual histidine and phosphate pKa values , 1997, Protein science : a publication of the Protein Society.
[7] T K Sawyer,et al. Src homology‐2 domains: Structure, mechanisms, and drug discovery , 1998, Biopolymers.
[8] G L Gilliland,et al. The three-dimensional structure of a glutathione S-transferase from the mu gene class. Structural analysis of the binary complex of isoenzyme 3-3 and glutathione at 2.2-A resolution. , 1992, Biochemistry.
[9] R. Panek,et al. Progress in the development of inhibitors of SH2 domains. , 2000, Current pharmaceutical design.
[10] J. Proudfoot,et al. Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. , 1999, Journal of medicinal chemistry.
[11] Tony Pawson,et al. Protein modules and signalling networks , 1995, Nature.
[12] S. Shoelson,et al. SH2 and PTB domain interactions in tyrosine kinase signal transduction. , 1997, Current opinion in chemical biology.
[13] J. M. Bradshaw,et al. Calorimetric investigation of proton linkage by monitoring both the enthalpy and association constant of binding: application to the interaction of the Src SH2 domain with a high-affinity tyrosyl phosphopeptide. , 1998, Biochemistry.
[14] J. Proudfoot,et al. Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding* , 1998, The Journal of Biological Chemistry.
[15] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[16] Joanna Trylska,et al. Thermodynamic linkage between the binding of protons and inhibitors to HIV‐1 protease , 2008, Protein science : a publication of the Protein Society.
[17] M. Gilson,et al. Prediction of pH-dependent properties of proteins. , 1994, Journal of molecular biology.
[18] M. Botfield,et al. Chapter 24. SH2 and SH3 Domains: Choreographers of Multiple Signaling Pathways , 1995 .
[19] S. Jakes,et al. Determination of receptor-ligand kinetic and equilibrium binding constants using surface plasmon resonance: application to the lck SH2 domain and phosphotyrosyl peptides. , 1995, Journal of medicinal chemistry.